The economic challenges countries face when adopting personalized medicine technologies provide an important illustration of many of the concepts articulated by János Kornai in his pioneering research on innovation in market-driven, capitalist surplus economies. In Chinese philosophy, Yin and Yang often represent contradictory yet inseparable opposites – two forces that not merely coexist, but are synergistic and mutually dependent. This concept is an apt analogy for the relationship between innovation and shortage in the health sector. Dangers arise from over-emphasizing the Yin of innovation over the Yang of access, and vice versa. If we over-constrain innovation, we die needlessly early and forfeit quality of life that innovations might have enabled. If we do not distribute access to innovations equitably, we diminish our humanity, suffer backlashes from populism and distrust of science and expertise, and risk social instability, even violent conflict.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
Arrow, K. J. (1963): Uncertainty and the Welfare Economics of Medical Care. American Economic Review, 53(5): 941–973.
-
Babiarz, K. S. – Eggleston, K. – Miller, G. – Zhang, Q. (2015): An Exploration of China’s Mortality Decline under Mao: A Provincial Analysis, 1950–80. Population Studies, 69(1): 39–56.
-
Berndt, E. R. – Trusheim, M. R. (2017): The Information Pharms Race and Competitive Dynamics of Precision Medicine. Paper Presented at the National Bureau of Economic Research Conference on Economic Dimensions of Personalized and Precision Medicine, Santa Monica, CA, September, 2017.
-
Čatić, T. (2016): Market Access Pricing in Central and Eastern Europe: Practical Guide to Successful Reimbursement in Bosnia and Herzegovina. ISPOR Central & Eastern Europe Network Newsletter 4(1). Https://Www.Ispor.Org/Ceenetwork/Newsletter/2016/Guide-To-Successful-Reimbursement-Bosnia-Herzegovina-And-Ukraine.Pdf.
-
Cybulski, J. S. – Clements, J. – Prakash, M. (2014): Foldscope: Origami-Based Paper Microscope. Plos One 9(6): E98781.
-
Chernew, M. E. – Newhouse, J. P. (2012): Health Care Spending Growth. Handbook of Health Economics, 2: 1–43.
-
Deaton, A. (2003): Health, Inequality, and Economic Development. Journal of Economic Literature, 41(1): 113–158.
-
Deaton, A. (2013): The Great Escape: Health, Wealth, and the Origins of Inequality. Princeton University Press.
-
Eggleston, K. (2016): Innovation, Shortage, and the Economics of Health Care Systems. In: Hámori, B. – Rosta, M. (eds): Constraints and Driving Forces in Economic Systems: Studies in Honour of János Kornai. Cambridge Scholars Publishing, pp. 15–29.
-
European Medicines Agency (2017): Herceptin. EMA.Europa.Eu. (Last Updated April 19, 2017, accessed September 5, 2017. http://Www.Ema.Europa.Eu/Ema/Index.Jsp?Curl=Pages/Medicines/Human/Medicines/000278/Human_Med_000818.Jsp&Murl=Menus/Medicines/Medicines.Jsp&Mid=WC0b01ac058001d125).
-
Frye, J. E. (ed.) (2015): International Drug Price Indicator Guide. MSH.Org. July 2, 2015. (Accessed September 5, 2017. http://Apps.Who.Int/Medicinedocs/Documents/S21982en/S21982en.Pdf.)
-
Gulácsi, L. – Orlewska, E. – Péntek, M. (2012): Health Economics and Health Technology Assessment in Central and Eastern Europe: A Dose of Reality. The European Journal of Health Economics, 13(5): 525–531. https://Link.Springer.Com/Article/10.1007%2Fs10198-012-0411-X.
-
Hamburg, M. – Collins, F. (2010): The Path to Personalized Medicine. The New England Journal of Medicine, 363(4): 301–304.
-
Kornai, J. – Eggleston, K. (2001): Welfare, Choice and Solidarity in Transition: Reforming the Health Sector in Eastern Europe. Cambridge, UK: Cambridge University Press.
-
Kornai, J. (2013): Dynamism, Rivalry, and the Surplus Economy: Two Essays on the Nature of Capitalism. Oxford University Press.
-
Management Sciences for Health (2014): Trastuzumab. Mshpriceguide.Org., January, 2014. (Accessed September 5, 2017. http://Mshpriceguide.Org/En/Single-Drug-Information/?Dmfid=147 1&Searchyear=2014).
-
Mayor, S. (2016): Differences in Availability of Cancer Drugs across Europe. The Lancet Oncology, 17(9): 1196. http://Www.Thelancet.Com/Journals/Lanonc/Article/PIIS1470-2045(16)30378-3/Fulltext.
-
NCK Pharma Solution (2017): Mylan Settles Trastuzumab Patent Litigation with Genentech and Roche. Nckpharma.Com., March 15, 2017. (Accessed September 5, 2017. https://Nckpharma.Com/Index.Php/Mylan-Settles-Trastuzumab-Patent-Litigation-With-Genentech-And-Roche/).
-
Neumann, P. J. – Ganiats, Th. G. – Russell, L. B. – Sanders, G. D. – Siegel, J. E. (2017) (eds): Cost Effectiveness in Health and Medicine. Oxford University Press.
-
Nobelprize.Org. (2017): Youyou Tu –Facts. Nobel Media AB 2014. (Accessed: 12 Oct 2017, <http://Www.Nobelprize.Org/Nobel_Prizes/Medicine/Laureates/2015/Tu-Facts.Html>
-
Ross-Degnan, D. – Lu, Ch. Y. – Chaiyakunapruk, N. – Wagner, A. K. (2015): Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand. PLOS ONE (2015). http://Journals.Plos.Org/Plosone/Article?Id=10.1371/Journal.Pone.0119945.
-
Singhroy, D. – Love, J. (2016): Proposal for the Inclusion of Trastuzumab Emtansine (T-Dm1) in the WHO Model List of Essential Medicines for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer. Knowledge Ecology International, December, 2016. (Accessed September 5, 2017. http://Www.Who.Int/Selection_Medicines/Committees/Expert/21/ Applications/S8_Trastuzumab_Emtansine.Pdf?Ua=1).
-
Wait, S. (2016): Access to Immuno-Oncology Therapies – European Policy Perspective. The American Journal of Managed Care, 20(2). http://Www.Ajmc.Com/Journals/Evidence-Based-Oncology/2016/February-2016/Access-To-Immuno-Oncology-Therapies-European-Policy-Perspective/P-1.
-
World Health Organization (2015): 19th WHO Model List of Essential Medicines. WHO.Int., April, 2015. (Accessed September 5, 2017. http://Www.Who.Int/Medicines/Publications/Essentialmedicines/ EML_2015_FINAL_Amended_NOV2015.Pdf?Ua=1).
-
Xu, Ch. (2017): Capitalism and Socialism: A Review of Kornai’s Dynamism, Rivalry, and the Surplus Economy. Journal of Economic Literature, 55(1): 191–208.
Please, download the file from HERE.
Please, download the file from HERE.
Corvinus University of Budapest
Department of Economics
Fővám tér 8 Budapest, H-1093, Hungary
Indexing and Abstracting Services:
- CABELLS Journalytics
- EconLit
- Elsevier GEO Abstracts
- GEOBASE
- Index Copernicus
- International Bibliographies IBZ and IBR
- JEL
- Referativnyi Zhurnal
- RePEc
- SCOPUS
- Social Science Citation Index
| 2021 | |
|---|---|
| Web of Science | |
| Total Cites WoS |
285 |
| Journal Impact Factor | 0,939 |
| Rank by Impact Factor | Economics 326/379 |
| Impact Factor without Journal Self Cites |
0,646 |
| 5 Year Impact Factor |
0,740 |
| Journal Citation Indicator | 0,34 |
| Rank by Journal Citation Indicator | Economics 389/570 |
| Scimago | |
| Scimago H-index |
15 |
| Scimago Journal Rank |
0,285 |
| Scimago Quartile Score | Economics and Econometrics (Q3) |
| Scopus | |
| Scopus Cite Score |
1,4 |
| Scopus CIte Score Rank |
Economics and Econometrics 436/696 (Q3) |
| Scopus SNIP |
0,507 |
| 2020 | |
| Total Cites | 275 |
| WoS | |
| Journal Impact Factor |
0,875 |
| Rank by | Economics 325/377 (Q4) |
| Impact Factor | |
| Impact Factor | 0,534 |
| without | |
| Journal Self Cites | |
| 5 Year | 0,500 |
| Impact Factor | |
| Journal | 0,38 |
| Citation Indicator | |
| Rank by Journal | Economics 347/549 (Q3) |
| Citation Indicator | |
| Citable | 37 |
| Items | |
| Total | 37 |
| Articles | |
| Total | 0 |
| Reviews | |
| Scimago | 13 |
| H-index | |
| Scimago | 0,292 |
| Journal Rank | |
| Scimago | Economics and Econometrics Q3 |
| Quartile Score | |
| Scopus | 225/166=1,4 |
| Scite Score | |
| Scopus | Economics and Econometrics 392/661 (Q3) |
| Scite Score Rank | |
| Scopus | 0,668 |
| SNIP | |
| Days from | 289 |
| submission | |
| to acceptance | |
| Days from | 447 |
| acceptance | |
| to publication |
| 2019 | |
|---|---|
| Total Cites WoS |
212 |
| Impact Factor | 0,914 |
| Impact Factor without Journal Self Cites |
0,728 |
| 5 Year Impact Factor |
0,650 |
| Immediacy Index |
0,156 |
| Citable Items |
45 |
| Total Articles |
45 |
| Total Reviews |
0 |
| Cited Half-Life |
3,9 |
| Citing Half-Life |
9,5 |
| Eigenfactor Score |
0,00015 |
| Article Influence Score |
0,052 |
| % Articles in Citable Items |
100,00 |
| Normalized Eigenfactor |
0,01891 |
| Average IF Percentile |
28,437 |
| Scimago H-index |
12 |
| Scimago Journal Rank |
0,439 |
| Scopus Scite Score |
214/165=1,3 |
| Scopus Scite Score Rank |
Economics and Econometrics 355/637 (Q3) |
| Scopus SNIP |
0,989 |
| Acta Oeconomica | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 900 EUR/article |
| Printed Color Illustrations | 40 EUR (or 10 000 HUF) + VAT / piece |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2023 | Online subsscription: 620 EUR / 750 USD Print + online subscription: 724 EUR / 880 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Oeconomica | |
|---|---|
| Language | English |
| Size | B5 |
| Year of Foundation |
1966 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 0001-6373 (Print) |
| ISSN | 1588-2659 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Oct 2022 | 3 | 0 | 0 |
| Nov 2022 | 13 | 0 | 0 |
| Dec 2022 | 8 | 0 | 0 |
| Jan 2023 | 22 | 0 | 0 |
| Feb 2023 | 4 | 0 | 0 |
| Mar 2023 | 4 | 0 | 0 |
| Apr 2023 | 0 | 0 | 0 |
The system paradigm revisited
Clarification and additions in the light of experiences in the post-socialist region
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory